Avricore Health 관리

관리 기준 확인 3/4

Avricore Health CEO는 Hector Bremner, Oct2019 에 임명되었습니다 의 임기는 5.08 년입니다. 총 연간 보상은 CA$ 321.44K, 67.2% 로 구성됩니다. 67.2% 급여 및 32.8% 보너스(회사 주식 및 옵션 포함). 는 € 142.95K 가치에 해당하는 회사 주식의 1.62% 직접 소유합니다. 142.95K. 경영진과 이사회의 평균 재임 기간은 각각 4.4 년과 5.4 년입니다.

주요 정보

Hector Bremner

최고 경영자

CA$321.4k

총 보상

CEO 급여 비율	67.2%
CEO 임기	5.1yrs
CEO 소유권	1.6%
경영진 평균 재임 기간	4.4yrs
이사회 평균 재임 기간	5.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Hector Bremner 의 보수는 Avricore Health 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-CA$3k
Mar 31 2024	n/a	n/a	-CA$341k
Dec 31 2023	CA$321k	CA$216k	-CA$701k
Sep 30 2023	n/a	n/a	-CA$1m
Jun 30 2023	n/a	n/a	-CA$901k
Mar 31 2023	n/a	n/a	-CA$824k
Dec 31 2022	CA$261k	CA$168k	-CA$818k
Sep 30 2022	n/a	n/a	-CA$782k
Jun 30 2022	n/a	n/a	-CA$1m
Mar 31 2022	n/a	n/a	-CA$1m
Dec 31 2021	CA$258k	CA$150k	-CA$2m
Sep 30 2021	n/a	n/a	-CA$2m
Jun 30 2021	n/a	n/a	-CA$2m
Mar 31 2021	n/a	n/a	-CA$2m
Dec 31 2020	CA$185k	CA$150k	-CA$1m
Sep 30 2020	n/a	n/a	-CA$909k
Jun 30 2020	n/a	n/a	-CA$1m
Mar 31 2020	n/a	n/a	-CA$2m
Dec 31 2019	CA$78k	CA$76k	-CA$2m

보상 대 시장: Hector 의 총 보상 ($USD 231.01K ) German 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 483.03K ).

보상과 수익: 회사가 수익성이 없는 동안 Hector 의 보상이 증가했습니다.

CEO

Hector Bremner (42 yo)

5.1yrs

테뉴어

CA$321,442

보상

Mr. Hector Bremner serves as Chief Executive Officer at Avricore Health Inc. since October 15, 2019 and has been its Director since April 2, 2020. He served as an Executive Vice-President of Branding, Stra...

리더십 팀

이름	위치	테뉴어	보상	소유권
Hector Bremner	CEO & Director	5.1yrs	CA$321.44k	1.62% € 143.0k
Kiriaki Smith	CFO & Corporate Secretary	5.3yrs	CA$167.95k	0.82% € 71.9k
Rodger Seccombe	CTO & Director	3.6yrs	CA$321.44k	4.84% € 425.4k
Will Seccombe	Communications Advisor	3.7yrs	데이터 없음	데이터 없음

4.4yrs

평균 재임 기간

43yo

평균 연령

경험이 풍부한 관리: 8VP1 의 관리팀은 경험 ( 4.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Hector Bremner	CEO & Director	4.6yrs	CA$321.44k	1.62% € 143.0k
Rodger Seccombe	CTO & Director	3.9yrs	CA$321.44k	4.84% € 425.4k
David Hall	Independent Chairman of the Board	8.8yrs	CA$81.43k	1.41% € 124.4k
Robert Sindelar	Independent Director	6.7yrs	CA$53.78k	0.88% € 77.1k
Alan Arnstein	Independent Director	7.6yrs	CA$53.78k	0.025% € 2.2k
Sherif Guorgui	Member of Advisory Board	5.4yrs	데이터 없음	데이터 없음
Philippe Ugnat	Member of Advisory Board	5.2yrs	데이터 없음	데이터 없음
Ray Chepsiuk	Member of Advisory Board	5.8yrs	데이터 없음	데이터 없음
Mark Zhou	Member of Advisory Board	5.7yrs	데이터 없음	데이터 없음
David Huston	Member of Advisory Board	5.4yrs	데이터 없음	데이터 없음
David Noshad	Member of Advisory Board	5.1yrs	데이터 없음	데이터 없음
Sotiris Antoniou	Member of Advisory Board	5.1yrs	데이터 없음	데이터 없음

5.4yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 이사회: 8VP1 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.

Avricore Health 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Avricore Health Inc., Annual General Meeting, Jun 20, 2024

Insufficient new directors

Avricore Health Inc. Announces Board Changes

Avricore Health Inc., Annual General Meeting, Jun 21, 2023

High number of new directors

Avricore Health Inc., Annual General Meeting, Jul 21, 2022

Recent updates

New major risk - Market cap size

Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.003 loss in 2Q 2023)

First quarter 2024 earnings released: EPS: CA$0.002 (vs CA$0.002 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.007 loss per share (vs CA$0.008 loss in FY 2022)

Avricore Health Inc., Annual General Meeting, Jun 20, 2024

New major risk - Market cap size

Insufficient new directors

Third quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 3Q 2022)

Avricore Health Inc. Expands Its Innovative Point-Of-Care Chronic and Infectious Disease Screening and Health- Data Management Platform, Healthtab

Second quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 2Q 2022)

Avricore Health Inc. Announces Board Changes

First quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.002 loss in 1Q 2022)

Avricore Health Inc., Annual General Meeting, Jun 21, 2023

Full year 2022 earnings released: CA$0.008 loss per share (vs CA$0.018 loss in FY 2021)

Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2021)

Second quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 2Q 2021)

High number of new directors

First quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.009 loss in 1Q 2021)

Avricore Health Inc., Annual General Meeting, Jul 21, 2022

High number of new and inexperienced directors

Full year 2021 earnings released: CA$0.018 loss per share (vs CA$0.019 loss in FY 2020)

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Avricore Health Inc Begins Patient Testing on the HealthTab™ Platform in Select Shoppers Drug Mart® Pharmacies

Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)

Avricore Health Inc. Patient Testing Has Begun on the First Deployment of the New HealthTab

Avricore Health Inc. Begins Patient Testing on First Deployment of New HealthTabTM-Integrated Afinion 2TM Analyzers in Initial Shoppers Drug Mart® Pharmacy Location

Avricore Health Inc. Signs Master Agreement to Pilot Healthtab Platform for Diabetes Management in Select Shoppers Drug Mart Pharmacies

Avricore Health Inc. Successfully Launches HealthTab™ in the First of 11 Shoppers Drug Mart Pilot Locations

Avricore Health's HealthTab Achieves Critical Milestones in Connecting New Testing Device

First quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.004 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.019 loss per share (vs CA$0.041 loss in FY 2019)

Avricore Health Inc. Signs Letter of Intent with Avrok Laboratories

Avricore Health Inc. announced that it has received CAD 1.54 million in funding

Whole Health Pharmacy Partners to Launch Avricore’s Healthtab™

New 90-day high: €0.36

Avricore Health Inc. announced that it expects to receive CAD 1.54 million in funding

Avricore Health Inc. Announces Board Changes

Avricore Health Inc. announced that it has received CAD 1.5 million in funding

Avricore Health Inc. Successfully Intergrates ID Now™ Rapid PCR Test Device, Offering Real-Time Covid-19 Reporting Direct from Instrument for First Time

Avricore Health Announces Management Changes

Third quarter 2020 earnings released: CA$0.003 loss per share

Avricore Health Inc. announced that it expects to receive CAD 1.5 million in funding

Healthtab Integrating New Device to Add Hba1c Blood Glucose Testing to Its Real-Time Data Reporting System

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령